Literature DB >> 11197239

Osteoporosis in a north american adult population with celiac disease.

D Meyer1, S Stavropolous, B Diamond, E Shane, P H Green.   

Abstract

OBJECTIVE: Osteoporosis, common in European and South American adults with celiac disease, has not been reported in those patients with celiac disease residing in North America. We therefore evaluated bone density in a group of patients from the United States.
METHODS: Patients (105 women and 23 men) with celiac disease, who had completed a questionnaire and had bone mineral density (BMD) measured by dual energy x-ray absorptiometry, were evaluated. The patients were an average age of 56 yr old (range 21-83 yr) and had been on a gluten-free diet from 0 months to 46 yr (mean 7.5 yr).
RESULTS: Osteoporosis (T score < -2.5) was present in 34% of the patients at the lumbar spine, 27% at the femoral neck, and 36% at the radius. Low bone mass (T score between -1.0 and -2.5) was present in 38% at the lumbar spine, 44% at the femoral neck, and 32% at the radius. When compared to age-matched controls, men were more severely affected than women. BMD did not differ between those on a gluten-free diet and those who had not begun therapy. BMD was remeasured 16 +/- 2 months after beginning a gluten-free diet in 5 patients; it increased by 7.5% at the femoral neck (p < 0.02). In 16 patients who had followed a gluten-free diet for an average of 12 yr, BMD remained stable over an additional 2 yr of observation.
CONCLUSIONS: Osteoporosis and low bone mass often affect North American adults with celiac disease, whether or not they are on dietary therapy. Routine screening for osteoporosis is indicated in patients with celiac disease.

Entities:  

Mesh:

Year:  2001        PMID: 11197239     DOI: 10.1111/j.1572-0241.2001.03507.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  58 in total

1.  Osteoporosis and gastrointestinal disease.

Authors:  Seymour Katz; Stuart Weinerman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-08

2.  Seronegative celiac disease: increased prevalence with lesser degrees of villous atrophy.

Authors:  Julian A Abrams; Beverly Diamond; Heidrun Rotterdam; Peter H R Green
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

3.  Review.

Authors:  Mohammad Azam; Maire Buckley; Richard J Farrell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-04

Review 4.  Celiac disease in Middle Eastern and North African countries: a new burden?

Authors:  Kassem Barada; Abbas Bitar; Mohamad Abdul-Razak Mokadem; Jana Ghazi Hashash; Peter Green
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

5.  Celiac disease: similar presentations in the elderly and young adults.

Authors:  Rupa Mukherjee; Ikenna Egbuna; Pardeep Brar; Lincoln Hernandez; Donald J McMahon; Elizabeth J Shane; Govind Bhagat; Peter H R Green
Journal:  Dig Dis Sci       Date:  2010-02-18       Impact factor: 3.199

6.  New and developing therapies for celiac disease.

Authors:  Christina A Tennyson; Suzanne K Lewis; Peter H R Green
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

7.  The Canadian Celiac Health Survey.

Authors:  Ann Cranney; Marion Zarkadas; Ian D Graham; J Decker Butzner; Mohsin Rashid; Ralph Warren; Mavis Molloy; Shelley Case; Vernon Burrows; Connie Switzer
Journal:  Dig Dis Sci       Date:  2007-02-22       Impact factor: 3.199

8.  Adult celiac disease in the elderly.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2008-12-07       Impact factor: 5.742

9.  Celiac disease in the Turkish population.

Authors:  Rengin Elsurer; Gonca Tatar; Halis Simsek; Yasemin H Balaban; Musa Aydinli; Cenk Sokmensuer
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

Review 10.  Celiac Disease-Musculoskeletal Manifestations and Mechanisms in Children to Adults.

Authors:  Haley M Zylberberg; Benjamin Lebwohl; Peter H R Green
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.